

# Targeting Phage Therapy 2025

June 10 - 11, 2025 – Berlin, Germany

---

## Accepted Poster Presentation List

Isolation and characterization of a highly virulent phage against clinical multidrug-resistant *Escherichia coli* isolates  
Ahu Reis, Karadeniz Technical University, Turkiye

Targeting biofilm-associated *Pseudomonas aeruginosa* using phage–antibiotic combination  
Anne Dalponte, FU Berlin, Germany

Development of a digital phagogram platform for accelerated matching of bacteriophages to multidrug-resistant pathogens  
Baptiste Bourguine, Precise Health SA, Switzerland

Epizootic situation on salmonellosis in private subsidiary farms of the Republic of Kazakhstan  
Bolat Yespembetov, Research institute for biological safety problems, Kazakhstan

Tailored phage selection for the treatment of chronic airway infections due to MDR *Pseudomonas aeruginosa*  
Christian van Delden, University Hospitals Geneva, Switzerland

From data to the bench: Identifying and testing phage therapy candidates to combat biofouling in seawater desalination plants  
Darwin Alexander Castillo, King Abdullah University of Science and Technology, Saudi Arabia

Disruption of biofilm by selected bacteriophages isolated from environmental samples  
Filip Wojnarowski, Adam Mickiewicz University Poznań, Poland

The DSMZ phage bank: A resource for phage research and therapy  
Filipa Martins, Leibniz Institute - DSMZ, Germany

Genomic diversity of bacteriophages infecting *Cronobacter* spp.  
Hana Drahovska, Comenius University in Bratislava, Slovak Republic

More-than-human-kinships with phages: An artistic and microbiological approach  
Harper Lethin, Reed College, United States of America

Analysis of the profiles of pro- and anti-inflammatory response in patients subjected to phage therapy  
Hubert Oskar Kasprzak, Hirsfeld Institute of Immunology and Experimental Therapy, Poland

Isolation and characterization of two lytic phages targeting *Salmonella enterica* from European poultry environments  
Ignacio Samuel Gómez-Cano, El Centro de Calidad Avícola y Alimentación Animal de la Comunidad Valenciana (CECAV), Spain

Addressing phage resistance: Designing effective phage cocktails against multi-drug resistant *Mycobacterium abscessus*  
Jun Hao Liew, ASTAR Infectious Diseases Lab/ASTAR, Singapore

Is the nihil a representative of a new genus of *Bacillus* viruses?  
Kacper Dudczak, Adam Mickiewicz University, Poznań, Poland

Characterization and genomic analysis of a new bacteriophage *Klebsiella pneumoniae* CTF-1  
Kübra Can Kurt, University of Health Science, Turkiye

Isolation and characterization of a novel bacteriophage targeting vancomycin-resistant *Enterococcus faecium*  
Laura Ribes-Martínez, Fundación Jiménez Díaz, Spain

Rapid and specific detection of pathogenic bacteria using recombinant receptor binding proteins of bacteriophages  
Leonie Reetz, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Germany

High-specificity phage cocktails against the highly successful and disseminated *S. aureus* Clonal Complex 8 (MRSA/MSSA)  
TBC - Universidad de Antioquia, Colombia

Monitoring bacteriophage therapy using nuclear medicine imaging  
Marek Moša, Charles University - Faculty of Science, Czech Republic

Characterisation of custom phages in a multidrug-resistant *Pseudomonas aeruginosa* urinary tract infection case  
Maria Chichashvili, G. Eliava Institute of Bacteriophages, Microbiology and Virology, Georgia

Strategies for the formulation of phage-based dosage forms  
Martin Benešík, MB Pharma/Masaryk University, Czech Republic

Translating phage therapy to human medicine  
Martin Starostka, FAGOFARMA, Czech Republic

Isolation, in vivo evaluation, and clinical use of phages for patients with special clinical needs  
Martina Durcik, Centre of Excellence for Biosensors, Instrumentation and Process Control, Slovenia

Characteristics of selected environmental bacteriophage vB\_SEN-Miriam1 infecting *Salmonella enterica* serovars  
Miriam Knefel, University of Gdansk, Poland

*Pseudomonas aeruginosa*-induced bilateral otitis media with different progression under topical phage therapy  
Miriam Waizer, University Hospital Regensburg, Germany

Development of phage therapy to treat ash canker  
TBC - University of Birmingham, United Kingdom

An alternative approach to syphilis treatment: Bacteriophage against *Treponema pallidum*  
Nazym Syrym, Research institute for biological safety problems, Kazakhstan

Microbiological, genomic, and structural mapping of two bacteriophages specific to *Salmonella enterica* serovar Typhimurium  
TBC - Cayetano Heredia University, Peru

Phage viability in cosmetic ingredients  
Simona Košiarčíková, MB PHARMA s.r.o., Czech Republic

Two novel bacteriophages vB\_Bm-S567 and vB\_BoMT-1/77 targeting multidrug resistant *Burkholderia cepacia* complex  
Sopiko Sturua, G.Eliava Institute of Bacteriophages, Microbiology and Virology, Georgia

Real-time LSM analysis of phage vB\_KpUKJ\_2 treatment and antibiotic synergy in *Klebsiella pneumoniae* biofilms  
Tinatini Tchatchiashvili, Jena University Hospital, Germany

Isolation of novel bacteriophages targeting clinical strains of *Klebsiella pneumoniae* and *Acinetobacter baumannii* and the development of phage-based therapeutic TRIOFAG®  
Vítězslav Fuglík, Charles University - Faculty of Science, Czech Republic

Evolution of ceftolozane/tazobactam resistance in carbapenem-resistant *Pseudomonas aeruginosa* under phage-antibiotic combination therapy  
Viviane Oliveira, Centro de Investigación Biomédica en Red - CIBER, Spain

Characterization of *Escherichia coli* bacteriophages isolated from wastewater in Bulgaria  
Yoana Krasimirova Kizheva, Sofia University "St. Kliment Ohridski", Bulgaria